Trial Profile

A Phase I, randomized, placebo-controlled, multi-center trial assessing pepinemab in Alzheimer's Disease

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 19 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pepinemab (Primary)
Indications Alzheimer's disease
Focus Adverse reactions
Sponsors Vaccinex

Most Recent Events

16 Mar 2021 According to a Vaccinex media release, enrollment is expected to begin in Q2.
13 Nov 2020 According to a Vaccinex media release, the company is planning to initiate this study in 2021 with partial funding support received from both the Alzheimers Association and from the Alzheimers Drug Discovery Foundation.
09 Mar 2020 According to a Vaccinex media release, enrollment of first patient is anticipated in mid-2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com